158 related articles for article (PubMed ID: 15390018)
21. Parallel double-blind study of pergolide in Parkinson's disease.
Jankovic J; Orman J
Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
[No Abstract] [Full Text] [Related]
22. An intermittent, controlled-rate, slow progressive degeneration model of Parkinson's disease: antiparkinson effects of Sinemet and protective effects of methylphenidate.
Fleming SM; Delville Y; Schallert T
Behav Brain Res; 2005 Jan; 156(2):201-13. PubMed ID: 15582106
[TBL] [Abstract][Full Text] [Related]
23. Treatment of Parkinson's disease with the partial dopamine agonist EMD 49980.
Bravi D; Davis TL; Mouradian MM; Chase TN
Mov Disord; 1993 Apr; 8(2):195-7. PubMed ID: 8097280
[TBL] [Abstract][Full Text] [Related]
24. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
Parkinson Study Group
Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
[TBL] [Abstract][Full Text] [Related]
25. Long-term efficacy and safety of pramipexole in advanced Parkinson's disease: results from a European multicenter trial.
Möller JC; Oertel WH; Köster J; Pezzoli G; Provinciali L
Mov Disord; 2005 May; 20(5):602-10. PubMed ID: 15726540
[TBL] [Abstract][Full Text] [Related]
26. Managing pathological gambling in Parkinson's disease with enteral levodopa/carbidopa infusions.
Gerschlager W; Bloem BR
Mov Disord; 2009 Sep; 24(12):1858-60. PubMed ID: 19514056
[No Abstract] [Full Text] [Related]
27. Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.
Hauser RA; Rascol O; Korczyn AD; Jon Stoessl A; Watts RL; Poewe W; De Deyn PP; Lang AE
Mov Disord; 2007 Dec; 22(16):2409-17. PubMed ID: 17894339
[TBL] [Abstract][Full Text] [Related]
28. Clinical inquiry. Which drugs work best for early Parkinson's disease?
Jain L; Benko R; Safranek S
J Fam Pract; 2012 Feb; 61(2):106-8. PubMed ID: 22312616
[TBL] [Abstract][Full Text] [Related]
29. Motor effects of the partial dopamine agonist (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (preclamol) in Parkinson's disease.
Metman LV; Sethy VH; Roberts JR; Bravi D; Hoff JI; Mouradian MM; Chase TN
Mov Disord; 1994 Sep; 9(5):577-81. PubMed ID: 7990854
[TBL] [Abstract][Full Text] [Related]
30. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
31. [Continuous dopaminergic stimulation by Duodopa in advanced Parkinson's disease: Efficacy and safety].
Annic A; Devos D; Seguy D; Dujardin K; Destée A; Defebvre L
Rev Neurol (Paris); 2009; 165(8-9):718-27. PubMed ID: 19150100
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, open-label, sequential study comparing preferences for carbidopa-levodopa orally disintegrating tablets and conventional tablets in subjects with Parkinson's disease.
Nausieda PA; Pfeiffer RF; Tagliati M; Kastenholz KV; DeRoche C; Slevin JT
Clin Ther; 2005 Jan; 27(1):58-63. PubMed ID: 15763606
[TBL] [Abstract][Full Text] [Related]
33. Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients.
Hinson VK; Goetz CG; Leurgans S; Fan W; Nguyen T; Hsu A
Clin Neuropharmacol; 2009; 32(4):189-92. PubMed ID: 19620848
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
Chen JJ; Swope DM; Dashtipour K
Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
[TBL] [Abstract][Full Text] [Related]
35. Levodopa induced motor complications in Thai Parkinson's disease patients.
Kulkantrakorn K; Tiamkao S; Pongchaiyakul C; Pulkes T
J Med Assoc Thai; 2006 May; 89(5):632-7. PubMed ID: 16756048
[TBL] [Abstract][Full Text] [Related]
36. A double-blind evaluation of ciladopa in Parkinson's disease.
Weiner WJ; Factor SA; Sanchez-Ramos J; Berger J
Mov Disord; 1987; 2(3):211-7. PubMed ID: 3332914
[TBL] [Abstract][Full Text] [Related]
37. [Drug therapy of Parkinson's disease].
Zhou XD
Zhonghua Shen Jing Jing Shen Ke Za Zhi; 1985 Aug; 18(4):193-6. PubMed ID: 4075905
[No Abstract] [Full Text] [Related]
38. [Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study].
Chaná P; Fierro A; Reyes-Parada M; Sáez-Briones P
Rev Med Chil; 2003 Jun; 131(6):623-31. PubMed ID: 12942590
[TBL] [Abstract][Full Text] [Related]
39. Slowing Parkinson's disease progression: recent dopamine agonist trials.
Pan T; Le W; Jankovic J
Neurology; 2004 Jan; 62(2):343; author reply 343-4. PubMed ID: 14750218
[No Abstract] [Full Text] [Related]
40. Duodenal levodopa infusion for advanced Parkinson's disease: 12-month treatment outcome.
Antonini A; Isaias IU; Canesi M; Zibetti M; Mancini F; Manfredi L; Dal Fante M; Lopiano L; Pezzoli G
Mov Disord; 2007 Jun; 22(8):1145-9. PubMed ID: 17661426
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]